Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease ...

Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to ...

Opus Genetics has dosed the first subject in its Phase I/II clinical trial of OPGx-Best1 gene therapy for the treatment of ...

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The differential diagnosis and workup of a suspected ...

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif., November 05, 2025--PolyActiva, a clinical-stage ...

Black patients with inherited retinal diseases who undergo genetic testing are less likely than White patients to receive a conclusive genetic diagnosis, new research shows. At one center, about 39% ...

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to | Amgen Ventures-backed ...

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...